Next question would be, did this person play a role in the 2 vs 4 dosing denial & of course if there's e-mail comments on it along these lines too, then --- gotcha,,,,big time.

The optics of this e-mail are bad, but for now, FDA could downplay it away in many ways. So let's see what the covid e-mails reveal.

Years ago i posted about a good friend showed Cytodyn/LL to an x Ceo of a world-wide pharma, & the Ceo said ---- the drug is outstanding & the problem is the Ceo.

With this e-mail --- nothings wrong with the drug.
So i'll be damned.

Shall see where e-mails take all this.
In the least, it helps to solidify LL having a smooth, FDA cruise this time around.

Which is all we asked for anyway.
Im happy with the substance Dr. J has pointed out about our 2024 FDA relationship & referencing "turned the page on a new chapter", & etc...

He'll keep the current Cytodyn status seperated from this past trashy, personal, toxic stuff & the company will benefit from that.

LL will show great signs @ the 1st trial, interim results.
Stepping forward into success.